Welcome to our dedicated page for Owlet news (Ticker: OWLT), a resource for investors and traders seeking the latest updates and insights on Owlet stock.
Owlet, Inc. reports business developments for a pediatric health platform built around smart infant monitoring, connected wearables, video monitoring and app-based health insights. Company news commonly covers FDA-cleared pediatric monitoring products, including BabySat, consumer monitoring systems such as Dream Duo, and software services including Owlet360 and pediatric telehealth features.
Recurring updates also include quarterly financial results, guidance, leadership and governance changes, DME distribution partnerships, product recognition, and initiatives tied to Owlet's pediatric health and sleep data platform. These announcements reflect the company's mix of consumer baby monitoring, prescription monitoring access, subscriptions and connected-care services.
Owlet (NYSE:OWLT) reported record Q3 2025 results: revenue $32.0M (+44.6% YoY), gross profit $16.2M (gross margin 50.6%), operating income $1.2M and net income $4.1M/b). Adjusted EBITDA was
Owlet (NYSE: OWLT) announced a partnership with Rhapsody on November 12, 2025 to connect infant monitoring data from Owlet’s FDA-cleared prescription pulse oximeter, BabySat, into electronic health record (EHR) workflows.
The integration uses standards-based connectivity to send clinically validated infant vital signs into provider EHRs, aiming to reduce custom development, minimize errors, and allow clinicians to view continuous, real-time home-monitoring data within existing patient records. The partnership is positioned to support scaling pediatric remote patient monitoring programs and strengthen home-to-hospital data sharing.
Owlet (NYSE: OWLT) announced that its Dream Sight baby monitor is the first and only monitor to earn the SGS Cybersecurity Mark, after testing by Brightsight and EU Type Certification by SGS Fimko Oy under the European Radio Equipment Directive (RED) Articles 3(3)(d) and (e).
Launched in September 2025, Dream Sight features 2K HD streaming, night vision, motion/sound detection, two-way audio, and temperature/humidity tracking, and can integrate with the FDA-cleared Dream Sock for clinically validated vital signs and wellness trends.
Owlet (NYSE: OWLT) will report third quarter 2025 financial results after market close on Thursday, November 13, 2025. The company said President & CEO Jonathan Harris and CFO Amanda Twede Crawford will host a conference call at 4:30 p.m. ET the same day to discuss results and provide a business update.
Participants can join by phone at 833-470-1428 (domestic) or 646-844-6383 (international) using Access Code 428622. A simultaneous webcast and replay will be available in the Events section of Owlet's Investor Relations website at investors.owletcare.com.
Owlet (NYSE: OWLT) priced an underwritten public offering of 4,196,000 shares of Class A common stock at $7.15 per share, with gross proceeds expected to be approximately $30.0 million.
The company granted underwriters a 30‑day option to purchase up to an additional 629,400 shares at the public offering price less underwriting discounts and commissions. The offering is expected to close on or about October 23, 2025, subject to customary closing conditions.
Owlet intends to use net proceeds to support continued commercialization, research and development, and general corporate purposes. William Blair and TD Cowen are joint bookrunners; Craig‑Hallum is co‑manager. The offering is made pursuant to an effective Form S‑3 registration statement.
Owlet (NYSE: OWLT) announced a proposed underwritten public offering of its Class A common stock on October 21, 2025. The company said it will grant underwriters a 30-day option to buy up to 15% additional shares at the offering price less underwriting discounts and commissions. All shares are being offered by Owlet, with net proceeds intended to support continued commercialization, research and development, and general corporate purposes.
William Blair and TD Cowen are joint bookrunners and Craig-Hallum is co-manager. The offering is subject to market conditions and will be made by prospectus supplement filed under Owlet’s effective Form S-3 (File No. 333-281556). Prospective investors can obtain the preliminary prospectus supplement from the underwriters or the SEC website.
Owlet (NYSE: OWLT) received CDSCO approval to distribute Dream Sock in India and plans a broader launch of Dream Sock, Dream Sight and Dream Duo in early 2026. The company says its wearable Dream Sock monitors oxygen and pulse for infants 0–18 months (2.5–13.6 kg) and pairs with the Dream App and Base Station for real-time alerts. Owlet noted India’s large birth cohort (~23 million babies expected in 2025), >80% urban smartphone penetration, and that its products are already used by 2 million families in 30+ countries.
Owlet (NYSE: OWLT) announced that on September 30, 2025 its Compensation Committee approved an equity inducement award for Jordan Thompson, Vice President and Corporate Controller, in connection with his hiring. The award consists of 129,863 restricted stock units (Inducement RSUs). Vesting: 33.33% on May 15, 2026, then the remainder in equal quarterly installments through May 15, 2028, subject to continued employment. The Committee approved the award using the NYSE employment inducement exemption under Rule 303A.08, so shareholder approval was not required.
Owlet (NYSE:OWLT) has launched its new Dream Sight™ HD video baby monitor and next-generation Dream Duo™ system. The Dream Sight, priced at $99.99, features 2K HD resolution, motion detection, two-way talk capabilities, and 256-bit encryption. It can be used standalone or integrated with the FDA-cleared Dream Sock.
The premium Dream Duo bundle, retailing at $379.99, combines Dream Sight with the medically-certified Dream Sock, which monitors baby's oxygen level, pulse rate, and sleep trends. Clinical data shows 96% of parents report reduced anxiety and 94% experience better sleep using Owlet products.
The products are available in the U.S., Canada, the UK, and Europe through major retailers including Amazon, Target, and Walmart.
Owlet (NYSE: OWLT) has announced the expansion of its medically-certified Dream Sock™ into South Africa, marking its presence across three continents including North America, Europe, and Africa. The Dream Sock, distributed as a Class C Medical Device with CE Marking, is designed for babies aged 0-18 months and monitors vital signs including pulse rate, oxygen level, and sleep patterns.
The device connects to the Owlet Dream App and Base Station, providing real-time health notifications to parents. The system includes Predictive Sleep Technology and can be paired with Owlet Cam® 2 for comprehensive monitoring. The product is NAPPI coded for medical aid reimbursement and available through major retailers in South Africa.